 |
| |
PROSTATE CANCER TESTING SET TO INCREASE ?
- If Minomic’s testing process establishes that BLCA38 has good sensitivity and specificity for detecting prostate cancer in urine, this will potentially provide the Company with a significant commercial opportunity, particularly in view of its existing small capital base and worldwide market potential of a test kit which could be developed following this result
- Minomic’s well advanced ability to identify and reliably test for biomarkers of diseases such as cancer is situated in a growing market. The technology shows promise for major opportunities for rapid product range extension in diseases where traditional tests are limited or inadequate.
-
Successful commercialisation of a prostate cancer test should give Minomic the ability to provide continuous funding for ongoing research and pipeline projects such as the Type 2 diabetes diagnostic test, funding for growth for all commercial facets of the business, including acquisition of complimentary assets.
- Recently the Company’s scientists made an important breakthrough in Minomic’s Prostate Cancer research revealing they have located the molecule from the prostate cancer cells to which BLCA-38 binds. This is a key milestone in the development of a diagnostic assay test for Prostate Cancer that has potential to be used in pathology labs worldwide.
|
Go Back |
|
 |
| |
PROSTATE CANCER TESTING SET TO INCREASE
Prostate Cancer tests are set to increase dramatically with the aid of a new diagnostic being developed...
|
| |
| Read More : |
| |
MINOMIC INTERNATIONAL TO COMMERCIALISE PROSTATE CANCER AND DIABETES (TYPE 2) DIAGNOSTICS
Minomic International Limited has commenced its international marketing.... |
| |
| Read More : |
|
